Another explanation for the unexpected HLA-G/HLA-E resistance of CART is that relevant HLA-G or HLA-E-mediated immune-inhibitory effects could rely not on direct interactions with CART but on bystander cells in the TME, a scenario not reflected by coculture experiments of CART with HLA-G/HLA-E expressing tumor cells. The gene discussed is HLA-G; the disease is neoplasm.